HC Wainwright & Co. Maintains Buy on BioXcel Therapeutics, Lowers Price Target to $5

Benzinga Newsdesk www.benzinga.com Negative 54.8%

Neg 54.8% Neu 0% Pos 0%

HC Wainwright & Co. analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and lowers the price target from $6 to $5.